FDA warns seniors to avoid this vaccine after deadly complications
Older adults are being warned against receiving the chikungunya vaccine before traveling.
The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved by the Food and Drug Administration (FDA) in November 2023 as the first of its kind.
The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus.
First Vaccine For Chikungunya Virus, An 'Emerging Global Health Threat,' Gets Fda Approval
But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications.
"FDA and CDC will continue the evaluation of post-marketing safety reports for Ixchiq," the release reads.
Read On The Fox News App
"While the safety of Ixchiq for use in individuals 60 years of age and older is being further assessed, FDA and CDC are recommending a pause in use of the vaccine in this age group. FDA and CDC will update the public when the agencies complete their evaluation of this safety issue."
The advisory follows reports of "serious adverse events," including neurologic and cardiac events in people who received the vaccine.
Two of 17 events resulted in death from severe complications. One death was caused by encephalitis, or inflammation in the brain, the alert stated.
Those who experienced adverse effects of the vaccine were reported to be between the ages of 62 and 89.
The FDA warned that Ixchiq, which contains a live, weakened version of chikungunya, may cause symptoms similar to the virus.
Typical symptoms of chikungunya include fever, severe joint pain, headache, muscle pain and a rash, according to the CDC.
Click Here To Sign Up For Our Health Newsletter
Most people recover within a week, but some may experience "severe and disabling" joint pain for weeks or months.
"This virus is in a similar category as dengue or Zika and is carried by the same mosquitoes," Fox News senior medical analyst Dr. Marc Siegel previously told Fox News Digital.
At the time of the vaccine's approval, the FDA described chikungunya as an "emerging global health threat," with at least five million cases reported over the past 15 years.
For more Health articles, visit www.foxnews.com/health
The FDA plans to conduct an "updated benefit-risk assessment" for Ixchiq use in those over 60 years of age, according to the notice.
Fox News Digital's Melissa Rudy contributed to this report.Original article source: FDA warns seniors to avoid this vaccine after deadly complications
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS
SUZHOU, China, June 2, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven Investigational New Drug (IND) approvals for registered clinical trials from both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA). All approvals focus on clinical-grade, off-the-shelf and allogeneic iPSC-derived cell therapy candidates targeting central nervous system (CNS) diseases with significant unmet medical needs, including: Parkinson's Disease (PD), the world's second most prevalent neurodegenerative disease affecting over 10 million patients globally (Phase I clinical trials in both China and the U.S.); Spinal Cord Injury (SCI), a major CNS disease impacting more than 10 million patients globally (First-in-Class; Phase I clinical trials in China and the U.S.); and Amyotrophic lateral sclerosis (ALS), a devastating rare neurodegenerative disease (First-in-Class; Phase I/II clinical trial in China and Phase I in the U.S.; designated as an Orphan Drug by the U.S. FDA). XellSmart has completed multiple cases of iPSC-derived dopaminergic neural progenitor cell therapy for patients with Parkinson's disease, including"the first case"in China. This clinical study was approved by the National Health Commission (NHC) of China. In the clinical study, clinical-grade iPSC-derived dopaminergic neural progenitor cells were transplanted into the putamen of the striatum in patients with moderate to advanced Parkinson's disease. With follow-up periods exceeding 12 months, no cell therapy-related adverse events have been observed. Multiple patients showed significant improvements in key efficacy indicators, including"on/off"time duration and MDS-UPDRS scores, as well as notable enhancements in non-motor symptoms. XellSmart is committed to developing clinical-grade, off-the-shelf allogeneic iPSC-derived cell therapies targeting central nervous system (CNS) diseases with no effective treatment options. XellSmart is at the forefront of advancing innovative iPSC-based therapies to address major and intractable CNS disorders:In 2023, China's first iPSC-derived cell therapy (XS228 injection), developed by XellSmart, was granted by FDA as Orphan Drug Designation (ODD) for the treatment of amyotrophic lateral sclerosis (ALS). In 2024, China's first national-level registered clinical study of an iPSC-derived cell therapy for Parkinson's disease—also developed by XellSmart—was approved and initiated, including the first case treated in China. In 2024, the world's first national-level registered clinical study of a subtype-specific iPSC-derived neural progenitor cell therapy (XS228 injection) for ALS was approved. Multiple patients, including the world's first ALS case treated with this approach, received therapy with good safety profiles and preliminary data showing slowed disease progression. In 2025, China's first registrational Phase I clinical trial of an off-the-shelf allogeneic iPSC-derived dopaminergic neural progenitor cell therapy (XS411 injection) for Parkinson's disease was launched, led by the National Neurological Disease Medical Center at Beijing Tiantan Hospital. In 2025, China's first randomized, double-blind, controlled Phase I/II clinical trial of XS411 injection was initiated to treat early-onset Parkinson's disease (EOPD), led by Huashan Hospital of Fudan University, a National Neurological Disease Medical Center. In 2025, the world's first registrational Phase I clinical trial of an off-the-shelf, allogeneic iPSC-derived subtype-specific neural progenitor cell therapy was launched by The Third Affiliated Hospital of Sun Yat-sen University, targeting spinal cord injury (SCI) — a major neurological disorder with no effective treatment. In 2025, the world's first Phase I/II registrational clinical trial of XS228 injection—an off-the-shelf, allogeneic iPSC-derived subtype-specific neural progenitor cell therapy—was initiated by Peking University Third Hospital, targeting ALS, a devastating rare neurodegenerative disease. XellSmart has established a fully dedicated, internationally competitive "All-In" team focusing on development of clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system (CNS) diseases that currently lack effective treatment options. XellSmart has built a portfolio of proprietary, globally leading industrial technologies and platforms, fueling sustained in-house innovation centered on its core business. To develop iPSC-derived cell therapy candidates, XellSmart has established and operates an R&D center, a B+ and A-grade GMP manufacturing facility, and a quality control center spanning over 5,000 square meters. Multiple clinical-grade iPSC-derived cell therapy candidates developed by XellSmart have completed core CMC development, with fully integrated clinical-grade manufacturing processes and quality control systems in place. XellSmart has successfully produced clinical batches of multiple GMP-grade iPSC-derived subtype-specific neural progenitor cell therapies, currently deployed in multiple clinical trials. XellSmart has secured multiple rounds of financing, collectively led by renowned market-driven venture capital firms including Qiming Venture Partners, Eli Lilly Asia Ventures, Sequoia Capital China (Hongshan), and others. View original content: SOURCE XellSmart Sign in to access your portfolio
Wall Street Journal
41 minutes ago
- Wall Street Journal
How Moderna Went From Pandemic Hero to Vaccine Victim
Moderna MRNA 1.84%increase; green up pointing triangle was once a darling of the first Trump administration, which went to great lengths to help the company develop its Covid-19 vaccine that protected millions of people from the virus. Now the biotech is caught in the crossfire of Trump 2.0 as vaccine-making comes under fire. In the latest setback for Moderna MRNA 1.84%increase; green up pointing triangle, the Food and Drug Administration on Friday approved its next-generation Covid shot for a narrower population of patients than the company intended. The approval grants use of the vaccine only in older adults and people aged 12 to 64 with health risks.
Yahoo
2 hours ago
- Yahoo
Exercise may stop colon cancer from returning — and more
For Monday, June 2, WGN's Ben Bradley and Lourdes Daurte have the latest on new medical information, including: More Coverage: WGN's Medical Watch Exercise may help prevent colon cancer from returning, according to results from a late-phase trial published Sunday, June 1 in the New England Journal of Medicine. The study looked at people who followed an exercise program after undergoing surgery and chemotherapy for Stage 3, or high-risk Stage 2 colon cancer. It found exercise could reduce the risk of the cancer returning, a new cancer diagnosis, or death by 28 percent. The study participants who reduced their risk had a coach assist them in exercising over the eight-year study period. The CDC is urging Americans to cancel their upcoming flights if they're not vaccinated against measles. The agency upgraded its health travel warning after discovering the virus is spreading on US airplanes. Measles infections have been detected at the country's biggest airports in recent months during a resurgence of the virus linked to low vaccination rates. It's estimated that around 10 percent of adults may lack immunity, either because they never received a measles vaccine or because their immunity has diminished over time. Moderna has won FDA approval for a new version of the COVID-19 vaccine. It will be made available during the upcoming respiratory virus season to people aged 65 and older, and those aged 12 to 64 with at least one underlying health condition that puts them at severe risk. It's the first big approval by the FDA since it required drug companies to expand their testing. The new vaccine is called MNEXSPIKE. Sign up for our Medical Watch newsletter. This daily update includes important information from WGN's Dina Bair and the Med Watch team, including, the latest updates from health organizations, in-depth reporting on advancements in medical technology and treatments, as well as personal features related to people in the medical field. Sign up here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
